Summit Therapeutics cites positive HARMONi-2 overall survival data
Summit Therapeutics said partner Akeso presented HARMONi-2 data showing ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive non-small-cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.